Neovacs S.A. (EPA:ALNEV)
France
· Delayed Price · Currency is EUR 0.0036
-0.0006 (-14.29%)
May 27, 2025, 5:35 PM CET
Neovacs Revenue
In the year 2024, Neovacs had annual revenue of 433.94K EUR, down -18.65%. Neovacs had revenue of 41.54K in the half year ending December 31, 2024, a decrease of -184.98%.
Revenue
433.94K
Revenue Growth
-18.65%
P/S Ratio
0.02
Revenue / Employee
21.70K
Employees
22
Market Cap
7.45K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 433.94K | -99.48K | -18.65% |
| Dec 31, 2023 | 533.41K | 532.30K | 47,868.71% |
| Dec 31, 2022 | 1.11K | -21.43K | -95.07% |
| Dec 31, 2021 | 22.54K | -7.24K | -24.32% |
| Dec 31, 2020 | 29.78K | -65.37K | -68.70% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EssilorLuxottica Société anonyme | 26.51B |
| Sanofi | 45.17B |
| Sartorius Stedim Biotech | 2.86B |
| bioMérieux | 3.98B |
| Eurofins Scientific SE | 6.95B |
| Ipsen | 3.57B |
| Virbac | 1.40B |
| emeis Société anonyme | 5.64B |